Development and validation of an LC-ESI-MS/MS quantification method for a potential γ-aminobutyric acid transporter 3 (GAT3) marker and its application in preliminary MS binding assays

Biomedical Chromatography

Volumn 27, Issue 5, 2013, Pages 641-654

  Polley, Maria ^a   Höfner, Georg ^a   Wanner, Klaus Theodor ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Binding assay; GAT3; LC ESI MS MS; Method development; Validation

Indexed keywords

AMINO ACIDS; AMMONIUM BICARBONATE; CELL CULTURE; DRUG PRODUCTS;

BINDING ASSAYS; GAT3; ITS APPLICATIONS; LC MS/MS(ESI); LC-ESI-MS/MS; LC/ESI-MS/MS; METHOD DEVELOPMENT; QUANTIFICATION METHODS; VALIDATION; Γ-AMINOBUTYRIC ACID;

MASS SPECTROMETRY;

4 AMINOBUTYRIC ACID CARRIER; BUFFER; GAMMA AMINOBUTYRIC ACID TRANSPORTER 3; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BINDING ASSAY; CELL STRAIN HEK293; CHEMICAL STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIQUID CHROMATOGRAPHY; SYNTHESIS;

EID: 84876331471     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2841     Document Type: Article

References (54)

1. Abraham RJ, Aboitiz N, Merrett J, Sherborne B and Whitcombe I. Conformational analysis. Part 34.1 An NMR investigation of the conformational equilibrium and intramolecular hydrogen bonding in nipecotic acid derivatives. Journal of the Chemical Society, Perkin Transactions 2 2000; 2382-2392; doi:10.1039/B007506J.
2. Ali FE, Bondinell WE, Dandridge PA, Frazee JS, Garvey E, Girard GR, Kaiser C, Ku TW, Lafferty JJ, Moonsammy GI, Oh H-J, Rush JA, Setler PE, Stringer OD, Venslavsky JW, Volpe BW, Yunger LM and Zirkle CL. Orally active and potent inhibitors of γ-aminobutyric acid uptake. Journal of Medicinal Chemistry 1985; 28: 653-660; doi: 10.1021/jm50001a020.
3. Andersen KE, Braestrup C, Groenwald FC, Joergensen AS, Nielsen EB, Sonnewald U, Soerensen PO, Suzdak PD and Knutsen LJS. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4, 4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidate. Journal of Medicinal Chemistry 1993; 36: 1716-1725; doi: 10.1021/jm00064a005.
4. Beleboni R, Carolino R, Pizzo A, Castellan-Baldan L, Coutinho-Netto J, dos Santos W and Coimbra NC. Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships. Cellular and Molecular Neurobiology 2004; 24: 707-728; doi: 10.1007/s10571-004-6913-z.
5. Bennett JJ and Yamamura H. Neurotransmitter Receptor Binding, 2nd edn. Raven Press: New York, 1985.
6. Borden LA. GABA Transporter heterogeneity: pharmacology and cellular localization. Neurochemistry International 1996; 29: 335-356; doi: 10.1016/0197-0186(95)00158-1.
7. Bouchard G, Pagliara A, Carrupt P-A, Testa B, Gobry V and Girault HH. Theoretical and experimental exploration of the lipophilicity of zwitterionic drugs in the 1, 2-dichloroethane/water system. Pharmaceutical Research 2002; 19: 1150-1159; doi: 10.1023/a:1019846125723.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248-254; doi: 10.1016/0003-2697(76)90527-3.
9. Bylund D, Deupree J and Toews M. Methods in Molecular Biology, Vol. 259, Receptor Signal Transduction Protocols, 2nd edn. Humana Press: Totowa, NJ, 2004.
10. a Calculation, n.d. Available from: http://www.chemaxon.com/marvin/sketch/index.php (accessed 10 November 2011).
11. Chen NH, Reith MEA and Quick MW. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pfluegers Archiv, European Journal of Physiology 2004; 447: 519-531.
12. Dalby NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000; 39: 2399-2407; doi: 10.1016/s0028-3908(00)00075-7.
13. Dalby NO. Inhibition of [gamma]-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. European Journal of Pharmacology 2003; 479: 127-137; doi: 10.1016/j.ejphar.2003.08.063.
14. Dhar TGM, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL and Gluchowski C. Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. Journal of Medicinal Chemistry 1994; 37: 2334-2342; doi: 10.1021/jm00041a012.
15. Evans JE, Frostholm A and Rotter A. Embryonic and postnatal expression of four gamma-aminobutyric acid transporter mRNAs in the mouse brain and leptomeninges. The Journal of Comparative Neurology 1996; 376: 431-446; doi: 10.1002/(sici)1096-9861(19961216)376:3<431: aid-cne6>3.0.co;2-3.
16. FDA. 2001. Guidance for Industry, Bioanalytical Method Validation. United States Food and Drug Administration: Washington, DC. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (accessed 14 February 2011).
17. Giardina WJ, Decker MW, Porsolt RD, Roux S, Collins SD, Kim DJB and Bannon AW. An evaluation of the GABA uptake blocker tiagabine in animal models of neuropathic and nociceptive pain. Drug Development Research 1998; 44: 106-113; doi: 10.1002/(sici)1098-2299(199806/07)44:2/3<106: aid-ddr8>3.0.co;2-q.
18. Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel M, Davidson N, Lester H and Kanner B. Cloning and expression of a rat brain GABA transporter. Science 1990; 249: 1303-1306; doi: 10.1126/science.1975955.
19. Haylett D. Textbook of Receptor Pharmacology, 2nd edn. CRC Press: Boca Raton, FL, 2003.
20. Hess M, Höfner G and Wanner K. Development and validation of a rapid LC-ESI-MS/MS method for quantification of fluoxetine and its application to MS binding assays. Analytical and Bioanalytical Chemistry 2011; 400: 3505-3515; doi: 10.1007/s00216-011-4997-0.
21. Hitzel L, Watt AP and Locker KL. An increased throughput method for the determination of partition coefficients. Pharmaceutical Research 2000; 17: 1389-1395; doi: 10.1023/a:1007546905874.
22. Høg S, Greenwood JR, Madsen KB, Larsson OM, Frolund B, Schousboe A, Krogsgaard-Larsen P and Clausen RP. Structure-activity relationships of selective GABA uptake inhibitors. Current Topics in Medicinal Chemistry 2006; 6: 1861-1882; doi: 10.2174/156802606778249801.
23. Hulme EC. Receptor-Ligand Interactions: A Practical Approach. Oxford University Press: New York, 1992.
24. Iversen L. GABA pharmacology - what prospects for the future? Biochemical Pharmacology 2004; 68: 1537-1540; doi: 10.1016/j.bcp.2004.06.039.
25. Kazakevich Y and Lobrutto R (eds). HPLC for Pharmaceutical Scientists. John Wiley & Sons: Hoboken, NJ, 2007.
26. Ketter TA and Wang PW. The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. The Journal of Clinical Psychiatry 2003; 64(suppl. 3): 15-20.
27. Kragler A, Höfner G and Wanner KT. Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4. European Journal of Medicinal Chemistry 2008; 43: 2404-2411; doi: 10.1016/j.ejmech.2008.01.005.
28. Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K and Gether U. SLC6 Neurotransmitter transporters: structure, function, and regulation. Pharmacological Reviews 2011; 63: 585-640; doi: 10.1124/pr.108.000869.
29. Krogsgaard-Larsen P, Falch E, Larsson OM and Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Research 1987; 1: 77-93; doi: 10.1016/0920-1211(87)90012-x.
30. Kromidas S (ed.). HPLC Richtig Optimiert: Ein Handbuch für Praktiker. Wiley-VCH: Weinheim, 2006.
31. Lehre AC, Rowley NM, Zhou Y, Holmseth S, Guo C, Holen T, Hua R, Laake P, Olofsson AM, Poblete-Naredo I, Rusakov DA, Madsen KK, Clausen RP, Schousboe A, White HS and Danbolt NC. Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Research 2011; 95: 70-81; doi: 10.1016/j.eplepsyres.2011.02.014.
32. Liu QR, López-Corcuera B, Mandiyan S, Nelson H and Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain. [Corrected.] Journal of Biological Chemistry 1993; 268: 2106-2112.
33. Madsen KK, Clausen RP, Larsson OM, Krogsgaard-Larsen P, Schousboe A and White HS. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. Journal of Neurochemistry 2009; 109: 139-144; doi: 10.1111/j.1471-4159.2009.05982.x.
34. Madsen KK, White HS and Schousboe A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacology and Therapeutics 2010; 125: 394-401; doi: 10.1016/j.pharmthera.2009.11.007.
35. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030; doi: 10.1021/ac020361s.
36. Meldrum BS and Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40: S2-S6; doi: 10.1111/j.1528-1157.1999.tb02087.x.
37. Mussini T, Covingtion A, Longhi P and Rondinini S. Criteria for standardization of pH measurements in organic solvents and water+organic solvent mixtures of moderate to high permittivities. Pure and Applied Chemistry 1985; 57: 865-876; doi: 10.1351/pac198557060865.
38. Neue UD, Phoebe CH, Tran K, Cheng Y-F and Lu Z. Dependence of reversed-phase retention of ionizable analytes on pH, concentration of organic solvent and silanol activity. Journal of Chromatography. A 2001; 925: 49-67; doi: 10.1016/s0021-9673(01)01009-3.
39. Pabel J, Faust M, Prehn C, Wörlein B, Allmendinger L, Höfner G and Wanner KT. Development of an (S)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] carba analogue inhibitor for murine γ-aminobutyric acid transporter type 4. ChemMedChem 2012; 7: 1245-1255; doi: 10.1002/cmdc.201200126.
40. Pagliara A, Carrupt P-A, Caron G, Gaillard P and Testa B. Lipophilicity profiles of ampholytes. Chemical Reviews 1997; 97: 3385-3400; doi: 10.1021/cr9601019.
41. Schaffer LC and Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. The American Journal of Psychiatry 1999; 156: 2014-2015.
42. Schmidt D and Lynch J. 2003a. MultiScreen® filter plates for PAMPA: data review and optimization of PAMPA and permeability assays.
43. Schmidt D and Lynch J. 2003b. MultiScreen® filter plates for PAMPA: evaluation of the reproducibility of parallel artificial membrane permeation assays (PAMPA).
44. Schoenberg MR, Frontera AT, Bozorg A, Hernandez-Frau P, Vale F and Benbadis SR. An update on epilepsy. Expert Review of Neurotherapeutics 2011; 11: 639-645; doi: 10.1586/ern.11.50.
45. Schousboe A, Sarup A, Larsson OM and White HS. GABA transporters as drug targets for modulation of GABAergic activity. Biochemical Pharmacology 2004; 68: 1557-1563; doi: 10.1016/j.bcp.2004.06.041.
46. Snyder LR, Kirkland JJ and Dolan JW. Ionic samples: reversed-phase, ion-pair, and ion-exchange chromatography. In Introduction to Modern Liquid Chromatography, 3rd edn. Wiley: Hoboken, NJ, 2010.
47. Sugano K, Hamada H, Machida M and Ushio H. High Throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. Journal of Biomolecular Screening 2001; 6: 189-196; doi: 10.1177/108705710100600309.
48. Suzdak PD, Frederiksen K, Andersen KE, Sørensen PO, Knutsen LJS and Nielsen EB. NNC-711, a novel potent and selective γ-aminobutyric acid uptake inhibitor: pharmacological characterization. European Journal of Pharmacology 1992; 224: 189-198; doi: 10.1016/0014-2999(92)90804-d.
49. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001; 42: 8-12; doi: 10.1046/j.1528-1157.2001.042suppl.3008.x.
50. Unger KK and Weber E. Handbuch der HPLC. GIT Verlag: Darmstadt, 1995.
51. Wohnsland F and Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. Journal of Medicinal Chemistry 2001; 44: 923-930; doi: 10.1021/jm001020e.
52. Zepperitz C, Höfner G and Wanner KT. MS-binding assays: kinetic, saturation, and competitive experiments based on quantitation of bound marker as exemplified by the GABA transporter mGAT1. ChemMedChem 2006; 1: 208-217; doi: 10.1002/cmdc.200500038.
53. Zhou Y, Holmseth S, Guo C, Hassel B, Hoefner G, Huitfeldt HS, Wanner KT and Danbolt NC. Deletion of the GABA transporter 2 (GAT2, SLC6A13) gene in mice leads to changes in liver and brain taurine contents. Journal of Biological Chemistry 2012a; 287: 35733-35746; doi: 10.1074/jbc.M112.368175.
54. Zhou Y, Holmseth S, Hua R, Lehre AC, Olofsson AM, Poblete-Naredo I, Kempson SA and Danbolt NC. The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. American Journal of Physiology. Renal Physiology 2012b; 302: F316-F328; doi: 10.1152/ajprenal.00464.2011.